Clinical Trials on Steroid Refractory Graft-Versus-Host Disease

Total 1562 results

AltruBio Inc.

Completed

Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

Steroid-refractory Acute Graft-versus-Host Disease | Treatment-refractory Acute Graft-versus-Host Disease

United States
Hannah Choe, MD
National Cancer Institute (NCI); Plexxikon

Terminated

Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

Acute Graft Versus Host Disease | Steroid Refractory Graft Versus Host Disease

United States
medac GmbH

Recruiting

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease (BALDER)

Steroid-refractory Acute Graft-versus-host Disease

Germany, Spain, France, Poland
Xenikos
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) (1802)

Steroid-Refractory Acute Graft Versus Host Disease

United States
Xenikos
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (2002)

Steroid-Refractory Acute Graft Versus Host Disease

United States, Belgium, Croatia, France, Germany, Italy, Netherlands, Spain, United Kingdom
medac GmbH

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (IDUNN)

Steroid-refractory Acute Graft-versus-host Disease

Spain, Germany, France, Poland, Sweden
Nanfang Hospital of Southern Medical University

Unknown

Efficacy and Safety of FMT Capsule Treating Steroid-refractory GI-aGvHD

Steroid-refractory Gastrointestinal Acute Graft Versus Host Disease

China
Columbia University
Incyte Corporation

Terminated

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Graft Vs Host Disease | Steroid Refractory GVHD

United States
University of Liege

Terminated

Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)

Chronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host Disease

Belgium
Anhui Provincial Hospital

Recruiting

A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD

Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)

China
The Korean Society of Hematopoietic Stem Cell Transplantation
Hoffmann-La Roche

Unknown

Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Steroid-Refractory Chronic GVHD

Korea, Republic of
MaaT Pharma

Available

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease (ATLAS)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

France
MaaT Pharma

Recruiting

MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (ARES)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

Spain, France, Germany, Austria, Belgium, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Hematopoietic and Lymphoid Cell Neoplasm | Steroid Refractory Graft Versus Host Disease

United States
Nationwide Children's Hospital

Terminated

Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

Graft Versus Host Disease | Acute GVH Disease | Steroid Refractory GVHD

United States
Therakos, Inc., a Mallinckrodt Company

Terminated

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

Steroid Refractory Acute Graft Versus Host Disease

United States, Spain, France, Austria, Germany, Hungary, Italy, United Kingdom
ReAlta Life Sciences, Inc.

Not yet recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (AURORA)

Steroid Refractory GVHD
ElsaLys Biotech

Available

Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease

Steroid Resistant Acute Graft Versus Host Disease

France
Jonsson Comprehensive Cancer Center

Withdrawn

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

Acute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease | Steroid Refractory Graft Versus Host Disease

United States
Novartis Pharmaceuticals

Available

Managed Access Programs for INC424, Ruxolitinib

Primary Myelofibrosis (PMF) | Polycythemia Vera (PV) | Post Polycythemia Myelofibrosis (PPV MF) | Thrombocythemia Myelofibrosis (PET-MF) | Severe/Very Severe COVID-19 Illness | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease...
Jules Bordet Institute
Macopharma; Belgian Hematological Society

Recruiting

Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

Refractory Chronic Graft Versus Host Disease (cGVHD)

Belgium
MaaT Pharma

Recruiting

Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 (ORION)

Steroid Refractory GVHD | Intestinal GVHD

France
Impatients N.V. trading as myTomorrows
Kamada, Ltd.

No longer available

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Alpha 1-Antitrypsin Deficiency | Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Steroid Refractory Acute Graft Versus Host Disease | Alpha-1 Proteinase Inhibitor | Alpha-1 Protease Inhibitor Deficiency | Acute Graft-Versus-Host Reaction Following Bone Marrow...
Yi-Lun Wang

Completed

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Steroid Refractory GVHD

Taiwan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Chronic Graft Versus Host Disease | Hematologic and Lymphocytic Disorder | Steroid Refractory Graft Versus Host Disease

United States
Jazz Pharmaceuticals

Completed

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Acute-graft-versus-host Disease | Graft-versus-host Disease

United States, Belgium, United Kingdom, Greece, Germany, Spain, France, Italy, Austria, Canada, Bulgaria, Croatia, Poland, Portugal
Grupo Espanol de trasplantes hematopoyeticos y...

Completed

Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. (CSM/EICH2010)

Chronic Graft-Versus-Host Disease

Spain
Mesoblast, Inc.
Quintiles, Inc.

Completed

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Grade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host Disease

United States
National Cancer Institute (NCI)

Terminated

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Graft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host Disease

United States
John Levine

Completed

Itacitinib for Low Risk GVHD

GVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-disease

United States
Fundación Pública Andaluza para la gestión de la...
Instituto de Salud Carlos III

Active, not recruiting

Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant (AlloBolome)

Graft-versus-host Disease

Spain
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids

Graft-Versus-Host Disease

United States
Mallinckrodt

Completed

Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

Graft-versus-Host Disease

United States, Australia, France, Italy, Austria, Germany, Portugal, Slovakia, Spain, Switzerland, Turkey, United Kingdom
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Graft-versus-Host Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease

United States
M.D. Anderson Cancer Center

Completed

Experience of Having Chronic Graft-Versus-Host Disease

Graft-Versus-Host Disease

United States
Karolinska Institutet
Region Stockholm

Terminated

Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease

Graft-Versus-Host Disease

Sweden
Ohio State University Comprehensive Cancer Center

Completed

Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease

Graft-Versus-Host Disease

United States
University of Michigan Rogel Cancer Center

Completed

The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease

Graft-Versus-Host Disease

United States
Dana-Farber Cancer Institute

Terminated

An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease

Chronic Graft-versus-Host-Disease | Oral Mucosal Disease Due to Graft-versus-host Disease

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Acute Graft-Versus-Host Disease

China
ASC Therapeutics

Not yet recruiting

ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Acute-graft-versus-host Disease
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-sen University; Xinqiao Hospital...

Recruiting

MSC for Treatment of cGVHD After Allo-HSCT

Chronic Graft-versus-host Disease

China
The First Affiliated Hospital of Soochow University

Recruiting

Fecal Microbiota Transplantation in Gut aGVHD Treated

Acute-graft-versus-host Disease

China
Navy General Hospital, Beijing

Recruiting

Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD

Chronic Graft-versus-host Disease

China
Genentech, Inc.

Completed

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Acute Graft-versus-host Disease

United States
Genentech, Inc.

Terminated

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Acute Graft-versus-host Disease

United States, Canada
Incyte Corporation

Completed

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Graft-versus-host Disease (GVHD)

United States
Incyte Corporation

Completed

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Graft-versus-host Disease (GVHD)

United States, Spain, Belgium, France, Italy, Korea, Republic of, Finland, United Kingdom, Germany, Israel, Switzerland, Austria, Australia, Czechia, Greece, New Zealand, Poland, Portugal, Taiwan

Clinical Trials on Steroid Refractory Graft-Versus-Host Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations